NovaBay Pharmaceuticals, Inc.
NovaBay Pharmaceuticals, Inc. (NBY) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · NBY · as of Sep 30, 2025
Ownership Breakdown
13
Institutional Holders
▲ 1 vs Q2
$289,925
Total Inst. Value
▲ $163,182 vs Q2
26.63M
Shares Outstanding
freeFloat 99.04%
226,659
13F Shares Held
▲ 8,137 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
NBY largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
VANGUARD GROUP INC pharmaceutical preparations | 84.5K | 29.03% | 29.03% | $108.14M | Nov 7, 2025 | NEW |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 51.7K | 17.77% | 17.77% | $66.20M | Nov 12, 2025 | ▲ 17.9K |
STATE STREET CORP pharmaceutical preparations | 29.3K | 10.07% | 10.07% | $37.51M | Nov 14, 2025 | NEW |
APOLLON WEALTH MANAGEMENT, LLC pharmaceutical preparations | 27.6K | 9.47% | 9.47% | $35.28M | Oct 17, 2025 | NEW |
GROUND SWELL CAPITAL, LLC pharmaceutical preparations | 19.2K | 6.58% | 6.58% | $24.52M | Nov 6, 2025 | NEW |
VIRTU FINANCIAL LLC pharmaceutical preparations | 11.1K | 3.81% | 3.81% | $14.00M | Nov 14, 2025 | NEW |
CITIGROUP INC pharmaceutical preparations | 2.3K | 0.80% | 0.80% | $2.99M | Nov 10, 2025 | NEW |
TOWER RESEARCH CAPITAL LLC (TRC) pharmaceutical preparations | 948 | 0.33% | 0.33% | $1.21M | Nov 14, 2025 | ▼ 4.5K |
BANK OF AMERICA CORP /DE/ pharmaceutical preparations | 48 | 0.02% | 0.02% | $61,000 | Feb 3, 2026 | ▼ 7 |
MORGAN STANLEY pharmaceutical preparations | 3 | 0.00% | 0.00% | $4,000 | May 27, 2026 | — held |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
1
Increased
+17.9K shares6
New Positions
first time holders2
Decreased
−4.5K shares5
Sold Out
fully exitedNet shares change (top 50)
+13.4K
+17.9K / −4.5K
Net new holders
+0
6 new / 5 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
NBY insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
0
Buy transactions
1
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Lazar David E. 10 percent owner | Oct 21, 2025 | Award | 6,388,000 | — | — | 6.39M | Form 4 ↗ |
Framework Ventures IV L.P. 10 percent owner | Oct 21, 2025 | C-Conversion | 56,806,080 | — | — | 56.81M | Form 4 ↗ |
Framework Ventures IV L.P. 10 percent owner | Oct 16, 2025 | Purchase | 2,702,703 | $0.01 | $27.0K | 2.70M | Form 4 ↗ |
R01 Fund LP 10 percent owner | Oct 21, 2025 | C-Conversion | 56,806,080 | — | — | 56.81M | Form 4 ↗ |
R01 Fund LP 10 percent owner | Oct 16, 2025 | Purchase | 2,702,703 | $0.01 | $27.0K | 2.70M | Form 4 ↗ |
Kazley Michael John Chief Executive Officer | Oct 21, 2025 | C-Conversion | 56,806,080 | — | — | 56.81M | Form 4 ↗ |
Kazley Michael John Chief Executive Officer | Oct 16, 2025 | Purchase | 2,702,703 | $0.01 | $27.0K | 2.70M | Form 4 ↗ |
Kazley Michael John Chief Executive Officer | Oct 16, 2025 | Award | 220,663 | — | — | 220.7K | Form 4 ↗ |
Kazley Michael John Chief Executive Officer | Oct 16, 2025 | Award | 134,375 | — | — | 134.4K | Form 4 ↗ |
Framework Ventures IV L.P. 10 percent owner | Oct 16, 2025 | J-Other | 220,663 | — | — | 220.7K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
NovaBay Pharmaceuticals, Inc. (NBY) is primarily owned by institutional investors, who hold approximately 0.8% of total shares outstanding. Company insiders own approximately 0.96%, while retail and public investors account for the remaining 98.19%.
The largest institutional shareholder of NovaBay Pharmaceuticals, Inc. is VANGUARD GROUP INC, holding approximately 84,488 shares — equal to 29.03% of outstanding shares — as of September 30, 2025.
A total of 13 institutional investors currently hold NBY stock, with a combined institutional value of approximately $289,925 as of the most recent 13F filing period.
Frequently asked questions
NBY ownershipNovaBay Pharmaceuticals, Inc. (NBY) is primarily owned by institutional investors, who hold approximately 0.8% of shares. The largest shareholder is VANGUARD GROUP INC with a 29.03% stake. Company insiders hold 0.96%. Data sourced from SEC Form 13F as of September 30, 2025.